• June 3-6, 2024
  • San Diego Convention Center, California

Sessions

Loading

ReCode Therapeutics

Monday, June 03, 2024
CP
Other
ReCode Therapeutics is a clinical-stage genetic medicines company using precision delivery to power the next wave of mRNA and gene correction therapeutics. ReCode’s Selective Organ Targeting (SORT) lipid nanoparticle (LNP) platform enables highly precise and targeted delivery of genetic medicines directly to the organs and cells implicated in disease, enabling improved efficacy and potency. ReCode’s lead programs include RCT1100 for the treatment of primary ciliary dyskinesia caused by pathogenic mutations in the DNAI1 gene, and RCT2100 for the treatment of cystic fibrosis patients who do not respond to currently approved CFTR modulators. RCT1100 and RCT2100 are inhaled disease-modifying mRNA-based therapies formulated using the SORT LNP delivery platform. ReCode is expanding its pipeline to develop potential therapies for other rare and common genetic diseases including musculoskeletal, central nervous system, liver and infectious disease indications
ReCode Therapeutics
Company Website: https://recodetx.com/
Lead Product in Development: RCT1100 and RCT2100 - Primary Ciliary Dyskinesia & Cystic Fibrosis

Company HQ City

Menlo Park

Company HQ State

CA

Company HQ Country

United States

CEO/Top Company Official

Shehnaaz Suliman

Development Phase of Primary Product

Phase I
Back to Session List

BIO DOUBLE HELIX SPONSORS

Thanks to our sponsors for supporting our mission to drive a revolution to cure patients, protect our climate, and nourish humanity.

Loading

BIO HELIX SPONSORS